286 related articles for article (PubMed ID: 16091996)
1. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
Sauder DN; Mamelak AJ
J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
[TBL] [Abstract][Full Text] [Related]
2. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
3. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
Katugampola RP; Lewis VJ; Finlay AY
Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
Langley RG; Gupta AK; Cherman AM; Inniss KA
J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
[TBL] [Abstract][Full Text] [Related]
7. A review of biologic treatments for psoriasis with emphasis on infliximab.
Pirzada S; Tomi Z; Gulliver W
Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
10. Integrating biologic therapies into a dermatology practice: practical and economic considerations.
Craze M; Young M
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S139-42. PubMed ID: 12894138
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapies in psoriasis: a new therapeutic approach.
Gisondi P; Girolomoni G
Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
[TBL] [Abstract][Full Text] [Related]
13. Nail psoriasis and biologics.
Noiles K; Vender R
J Cutan Med Surg; 2009; 13(1):1-5. PubMed ID: 19298765
[TBL] [Abstract][Full Text] [Related]
14. Biologic therapies for psoriasis. A systematic review.
Boehncke WH; Prinz J; Gottlieb AB
J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
16. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
Clark L; Lebwohl M
J Am Acad Dermatol; 2008 Mar; 58(3):443-6. PubMed ID: 18083274
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
19. New biologic therapies for psoriatic disease.
Bohjanen KA; Prawer SE
Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
[TBL] [Abstract][Full Text] [Related]
20. Biological therapy and nail psoriasis.
Lawry M
Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
